I-MAB American Depositary Shares
Symbol: IMAB (NASDAQ)
2.55
▲ (26.62%) 0.535
Company Description:
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Key Stats
- Today's Open: $2.341
- Today's High: $2.639
- Today's Low: $2.265
- Today's Volume: 2.67M
- Yesterday Close: $2.01
- Yesterday High: $2.125
- Yesterday Low: $1.9401
- Yesterday Volume: 269.10K
- Last Min Volume: 1.20K
- Last Min High: $2.545
- Last Min Low: $2.54
- Last Min VWAP: $2.545
Company Profile
- Name: I-MAB American Depositary Shares
- Website: https://www.i-mabbiopharma.com
- Listed Date: 2020-01-17
- Location: ,
- Market Status: Active
- CIK Number: 0001778016
- SIC Code:
- SIC description:
- Market Cap: $164.14M
- Round Lot: 100
- Outstanding Shares: 81.66M
- Asset Type: ADRC
RECENT FILINGS FOR IMAB
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-01 | 6-K | View |
| 2025-08-01 | F-6EF | View |
| 2025-07-17 | 6-K | View |
| 2025-07-11 | 6-K | View |
| 2025-07-11 | 424B5 | View |
| 2025-07-11 | 6-K/A | View |
| 2025-07-02 | 6-K | View |
| 2025-06-26 | 6-K | View |
| 2025-06-12 | 6-K | View |
| 2025-06-02 | 6-K | View |
| 2025-05-30 | 6-K | View |
| 2025-05-15 | EFFECT | View |
| 2025-05-15 | 6-K | View |
| 2025-05-02 | F-3 | View |
| 2025-04-30 | 6-K | View |
| 2025-04-04 | 6-K | View |
| 2025-04-03 | 6-K | View |
| 2025-04-03 | 20-F | View |
| 2025-03-21 | 6-K | View |
| 2025-03-07 | 6-K | View |
Latest News on IMAB